



(12) Translation of
European patent specification

(11) NO/EP 2384318 B1

NORWAY

(19) NO

(51) Int Cl.

C07C 311/29 (2006.01)

A61K 31/18 (2006.01)

A61K 31/472 (2006.01)

A61K 31/4725 (2006.01)

A61K 31/517 (2006.01)

A61K 31/662 (2006.01)

A61K 31/675 (2006.01)

A61K 45/06 (2006.01)

A61K 47/54 (2017.01)

A61P 1/06 (2006.01)

A61P 13/12 (2006.01)

C07D 217/04 (2006.01)

C07D 401/12 (2006.01)

C07F 9/38 (2006.01)

C07F 9/40 (2006.01)

C07F 9/572 (2006.01)

C07F 9/62 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.03.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.11.15
(86)	European Application Nr.	09796924.0
(86)	European Filing Date	2009.12.30
(87)	The European Application's Publication Date	2011.11.09
(30)	Priority	2008.12.31, US, 141853 P 2009.04.15, US, 169509 P 2009.08.28, US, 237842 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Ardelyx, Inc., 34175 Ardenwood Blvd., Fremont, California 94555, US-USA
(72)	Inventor	CHARMOT, Dominique, 1150 Steinway Avenue, Campbell California 95008, US-USA JACOBS, Jeffrey, W., 505 Cornell Avenue, San Mateo California 94402, US-USA LEADBETTER, Michael, Robert, 335 Beverly Avenue, San Leandro California 94577, US-USA NAVRE, Marc, 2708 Wemberly Drive, Belmont California 94002, US-USA CARRERAS, Chris, 910 Chevy Street, Belmont California 94002, US-USA BELL, Noah, 2172 Blake Street, No. 10, Berkeley California 94704, US-USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS**


(56) References

Cited: WO-A1-01/17954, WO-A1-03/048129, ERTL P ET AL: "FAST CALCULATION OF MOLECULAR POLAR SURFACE AREA AS A SUM OF FRAGMENT-BASED CONTRIBUTIONS AND ITS APPLICATION TO THE PREDICTION OF DRUG TRANSPORT PROPERTIES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 43, no. 20, 1 January 2000 (2000-01-01), pages 3714-3717, XP002942715 ISSN: 0022-2623 cited in the application, WO-A1-2006/032372, US-A1- 2007 135 383, WO-A1-2004/085404

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav:

1. Forbindelse, eller farmasøytisk akesptabelt salt derav, hvor forbindelsen har følgende struktur (X)




hvor: n er 2;

NHE har en av de følgende strukturer:









L er en polyalkylenglykol-linker; og






Kjernen er valgt fra gruppen bestående av:















2. Forbindelse ifølge krav 1, hvor L er en polyetylenglykol linker.







3. Forbindelse ifølge hvilket som helst af kravene 1-2, hvor forbindelsen er valgt fra:



























og




eller et farmasøytisk akseptabelt salt derav.

4. Forbindelse ifølge hvilket som helst av kravene 1-2, hvor forbindelsen er valgt fra:













og




5. Forbindelse ifølge hvilket som helst av kravene 1-2, hvor forbindelsen er valgt fra:






og



6. Forbindelse ifølge hvilket som helst af kravene 1-3 hvor forbindelsen er



7. Farmasøytisk sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1-6, eller en stereoisomer eller farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer, fortynningsmiddel eller eksipient.

8. Forbindelse ifølge hvilket som helst av kravene 1-6 for anvendelse ved behandling av irritabel tarmsyndrom.

9. Forbindelse ifølge hvilket som helst av kravene 1-6 for anvendelse ved behandling av sluttstadium nyresykdom.

10. Forbindelse ifølge hvilket som helst av kravene 1-6 for anvendelse ved behandling av kronisk nyresykdom.

11. Forbindelse ifølge hvilket som helst av kravene 1-6 for anvendelse i behandlingen av forstoppelse i forbindelse med cystisk fibrose.